MREO · Insider Trading
Mereo BioPharma Group plc American Depositary Shares
Every open-market purchase and sale reported by MREO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | Annalisa Jenkins | Director | A | +172,848 deriv. | — |
| 2026-02-27 | Deepika Pakianathan | Director | A | +66,000 deriv. | — |
| 2026-02-27 | Daniel Shames | Director | A | +162,163 deriv. | — |
| 2026-02-27 | Anders Ekblom | Director | A | +199,560 deriv. | — |
| 2026-02-27 | Michael S Wyzga | Director | A | +66,000 deriv. | — |
| 2026-02-27 | Pierre Jacquet | Director | A | +172,848 deriv. | — |
| 2026-02-27 | Jeremy Bender | Director | A | +183,533 deriv. | — |
| 2026-02-27 | Marc J Yoskowitz | Director | A | +162,163 deriv. | — |
| 2026-02-02 | Christine Ann Fox | Chief Financial Officer | A | +701,000 deriv. | — |
| 2026-02-02 | Charles Sermon | General Counsel | A | +716,000 deriv. | — |
| 2026-02-02 | Alexandra Hughes-Wilson | See Remarks | A | +440,000 deriv. | — |
| 2026-02-02 | John A. Lewicki | Chief Scientific Officer | A | +331,550 deriv. | — |
| 2026-02-02 | Denise Scots-Knight | Chief Executive Officer | A | +1,860,000 deriv. | — |
| 2025-02-06 | Deepika Pakianathan | Director | A | +55,000 deriv. | — |
| 2025-02-06 | Anders Ekblom | Director | A | +74,054 deriv. | — |
| 2025-02-06 | Pierre Jacquet | Director | A | +70,243 deriv. | — |
| 2025-02-06 | Michael S Wyzga | Director | A | +85,487 deriv. | — |
| 2025-02-06 | Marc J Yoskowitz | Director | A | +68,719 deriv. | — |
| 2025-02-06 | Daniel Shames | Director | A | +68,719 deriv. | — |
| 2025-02-06 | Jeremy Bender | Director | A | +71,768 deriv. | — |
| 2025-02-06 | Annalisa Jenkins | Director | A | +70,243 deriv. | — |
| 2025-01-28 | Alexandra Hughes-Wilson | See Remarks | A | +154,000 deriv. | — |
| 2025-01-28 | Christine Ann Fox | Chief Financial Officer | A | +262,000 deriv. | — |
| 2025-01-28 | Denise Scots-Knight | Chief Executive Officer | A | +825,000 deriv. | — |
| 2025-01-28 | Charles Sermon | General Counsel | A | +262,000 deriv. | — |
| 2025-01-28 | John A. Lewicki | Chief Scientific Officer | A | +116,000 deriv. | — |
| 2024-09-16 | Denise Scots-Knight | Chief Executive Officer | Sell | −88,657 | −$381.42K |
| 2024-09-16 | John A. Lewicki | Chief Scientific Officer | Sell | −16,149 | −$69.48K |
| 2024-09-16 | Christine Ann Fox | Chief Financial Officer | Sell | −28,286 | −$121.69K |
| 2024-09-16 | Charles Sermon | General Counsel | Sell | −30,926 | −$133.05K |
| 2024-09-16 | Alexandra Hughes-Wilson | See Remarks | Sell | −148,110 | −$637.20K |
| 2024-09-13 | Christine Ann Fox | Chief Financial Officer | M | +60,000 | — |
| 2024-09-13 | Denise Scots-Knight | Chief Executive Officer | M | +188,060 | — |
| 2024-09-13 | Charles Sermon | General Counsel | M | +65,600 | — |
| 2024-09-13 | Alexandra Hughes-Wilson | See Remarks | M | +208,333 | +$206.42K |
| 2024-09-13 | John A. Lewicki | Chief Scientific Officer | M | +46,000 | — |
| 2024-08-23 | Deepika Pakianathan | Director | MIXED | — | −$315.09K |
| 2024-06-27 | Christine Ann Fox | Chief Financial Officer | Sell | −42,429 | −$147.88K |
| 2024-06-27 | Denise Scots-Knight | Chief Executive Officer | Sell | −132,985 | −$463.49K |
| 2024-06-27 | Alexandra Hughes-Wilson | See Remarks | Sell | −33,102 | −$115.37K |
| 2024-06-27 | John A. Lewicki | Chief Scientific Officer | Sell | −24,224 | −$84.43K |
| 2024-06-27 | Charles Sermon | General Counsel | Sell | −46,389 | −$161.68K |
| 2024-06-25 | Alexandra Hughes-Wilson | See Remarks | M | +60,000 | — |
| 2024-06-25 | Christine Ann Fox | Chief Financial Officer | M | +90,000 | — |
| 2024-06-25 | Charles Sermon | General Counsel | M | +98,400 | — |
| 2024-06-25 | John A. Lewicki | Chief Scientific Officer | M | +69,000 | — |
| 2024-06-25 | Denise Scots-Knight | Chief Executive Officer | M | +282,090 | — |
| 2024-06-17 | Michael S Wyzga | Director | A | +25,050 | +$99.95K |
| 2024-06-17 | Rubric Capital Management LP | 10%+ Owner | A | +3,508,700 deriv. | — |
| 2024-06-17 | Jeremy Bender | Director | A | +12,550 | +$50.07K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Denise Scots-Knight | Chief Executive Officer | 868,967 | $238.97K |
| Charles Sermon | General Counsel | 219,061 | $60.24K |
| Alexandra Hughes-Wilson | See Remarks | 134,483 | $36.98K |
| Christine Ann Fox | Chief Financial Officer | 108,443 | $29.82K |
| Deepika Pakianathan | Director | 105,244 | $28.94K |
| John A. Lewicki | Chief Scientific Officer | 92,826 | $25.53K |
| Michael S Wyzga | Director | 25,050 | $6.89K |
| Jeremy Bender | Director | 12,550 | $3.45K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MREO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.